VAZALORE’s unique delivery system is intended to predictably release aspirin in the duodenum and decrease exposure to the stomach, which is the most susceptible part of the GI tract to NSAID-induced local gastric injury.

VAZALORE is specially designed to help protect the stomach

Preassociating the aspirin in VAZALORE to our pharmaceutical lipid limits the aspirin from interacting with similar naturally occurring phospholipids in the stomach lining, helping to prevent local gastric injury.

LIMITS DIRECT CONTACT
VAZALORE’s complex remains stable in the low pH of the stomach, limiting direct contact between aspirin and the gastric mucosa

TARGETED DELIVERY
Once the complex arrives in the duodenum, it dissociates in the higher-pH environment and aspirin is free to be absorbed

FAST, PREDICTABLE ABSORPTION
This drug delivery system is intended to predictably release aspirin in the duodenum to optimize absorption

REASSEMBLES DURING REFLUX
Even if reflux occurs and aspirin and lipidic excipients return to the stomach, they reassemble into the complex, limiting direct stomach contact

VAZALORE is available in 81 mg and 325 mg doses

for secondary prevention of vascular events

for secondary prevention of vascular events; pain reliever; fever reducer
HEART PROTECTION WITH THEIR STOMACH IN MIND™

With VAZALORE, your patients will receive the benefits of the first major innovation in aspirin therapy in over 50 years.

This innovative, FDA-approved liquid-filled aspirin capsule offers:

- **Bioequivalence to immediate release** aspirin with fast predictable antiplatelet activity\(^1\)
- A unique, lipid-based delivery system designed to **help protect the stomach**
- **Targeted release** in the duodenum to optimize absorption

**VAZALORE 325 mg** has rigorous clinical studies\(^2,3\)

See **325 mg Clinical Data sheet** on VazaloreHCP.com or scan the QR code below.

**References:**


To learn more about how VAZALORE can help your patients, visit VazaloreHCP.com

©2022 PLx Pharma Inc. All rights reserved.